ATE70717T1 - Vermehrung der antigenimmunogenizitaet. - Google Patents
Vermehrung der antigenimmunogenizitaet.Info
- Publication number
- ATE70717T1 ATE70717T1 AT87304005T AT87304005T ATE70717T1 AT E70717 T1 ATE70717 T1 AT E70717T1 AT 87304005 T AT87304005 T AT 87304005T AT 87304005 T AT87304005 T AT 87304005T AT E70717 T1 ATE70717 T1 AT E70717T1
- Authority
- AT
- Austria
- Prior art keywords
- antigen
- cells
- monoclonal antibody
- targeting
- specific
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 5
- 102000036639 antigens Human genes 0.000 title abstract 5
- 108091007433 antigens Proteins 0.000 title abstract 5
- 230000005847 immunogenicity Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- 239000002671 adjuvant Substances 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004044 response Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6056—Antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868610983A GB8610983D0 (en) | 1986-05-06 | 1986-05-06 | Enhancement of antigen immunogenicity |
| EP87304005A EP0245078B1 (de) | 1986-05-06 | 1987-05-05 | Vermehrung der Antigenimmunogenizität |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE70717T1 true ATE70717T1 (de) | 1992-01-15 |
Family
ID=10597389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT87304005T ATE70717T1 (de) | 1986-05-06 | 1987-05-05 | Vermehrung der antigenimmunogenizitaet. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4950480A (de) |
| EP (1) | EP0245078B1 (de) |
| JP (1) | JPH0674210B2 (de) |
| AT (1) | ATE70717T1 (de) |
| DE (1) | DE3775458D1 (de) |
| GB (1) | GB8610983D0 (de) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK8189A (da) * | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
| US5173293A (en) * | 1989-02-23 | 1992-12-22 | Becton Dickinson And Company | Anti-T-cell antibodies as adjuvants |
| GB8907310D0 (en) * | 1989-03-31 | 1989-05-17 | Medical Res Council | Heteroconjugates |
| CA2015515C (en) | 1990-01-03 | 1999-12-07 | Jean-Marie Saint-Remy | Pharmaceutical compositions containing antigen-antibody complexes and uses therefor |
| US6248332B1 (en) | 1990-10-05 | 2001-06-19 | Medarex, Inc. | Targeted immunostimulation with bispecific reagents |
| DE69130709T3 (de) * | 1990-10-05 | 2005-12-22 | Celldex Therapeutics, Inc. | Gezielte immunostimulierung mit bispezifischen stoffen |
| US5107060A (en) * | 1990-10-17 | 1992-04-21 | Mobil Oil Corporation | Thermal cracking of mercury-containing hydrocarbon |
| GB9200117D0 (en) * | 1992-01-06 | 1992-02-26 | Connaught Lab | Production of recombinant chimeric proteins for vaccine use |
| GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
| CA2105629A1 (en) * | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
| US5686078A (en) * | 1992-09-14 | 1997-11-11 | Connaught Laboratories, Inc. | Primary and secondary immunization with different physio-chemical forms of antigen |
| JPH08505625A (ja) | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性ｔリンパ球応答の誘導 |
| EP0833929B1 (de) * | 1995-06-07 | 2008-05-14 | Sanofi Pasteur Limited | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
| ATE395422T1 (de) | 1995-06-07 | 2008-05-15 | Sanofi Pasteur Ltd | Chimäre antikörper zur abgabe von antigenen an selektierte zellen des immunsystems |
| ES2309992T3 (es) * | 1995-10-20 | 2008-12-16 | University Of Nebraska Board Of Regents | Composiciones y procedimientos para incrementar las respuestas inmunes mediadas por celulas presentadoras de antigeno. |
| US20080286228A1 (en) * | 1995-10-20 | 2008-11-20 | Tarantolo Stefano R | Compositions and methods for enhancing immune responses mediated by antigen-presenting cells |
| JP2000503003A (ja) * | 1995-12-22 | 2000-03-14 | イムノメディクス，インコーポレイテッド | 多段階カスケード増強ワクチンの効果を高めるための免疫接合体の使用 |
| JP2002515734A (ja) * | 1996-01-02 | 2002-05-28 | カイロン コーポレイション | 遺伝子改変された樹状細胞により媒介される免疫刺激 |
| US6060054A (en) * | 1996-04-10 | 2000-05-09 | National Jewish Medical And Research Center | Product for T lymphocyte immunosuppression |
| US8038994B2 (en) * | 1996-05-15 | 2011-10-18 | Quest Pharmatech Inc. | Combination therapy for treating disease |
| US20060159688A1 (en) * | 1996-05-15 | 2006-07-20 | Ragupathy Madiyalakan | Method for diagnosing efficacy of xenotypic antibody therapy |
| WO1997042973A1 (en) * | 1996-05-15 | 1997-11-20 | Altarex, Corp. | Method and composition for reconforming multi-epitopic antigens to initiate an immune response |
| FR2759296B1 (fr) * | 1997-02-07 | 1999-04-09 | Commissariat Energie Atomique | Complexe non-covalent comprenant au moins un anticorps et un element de liaison aux immunoglobulines associe a une substance active, son procede de preparation et ses applications |
| US20020025315A1 (en) * | 1998-01-14 | 2002-02-28 | Naveen N. Anand | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
| US8647864B2 (en) | 1999-04-14 | 2014-02-11 | Novartis Ag | Compositions and methods for generating an immune response utilizing alphavirus-based vector systems |
| GB9924351D0 (en) * | 1999-10-14 | 1999-12-15 | Brennan Frank | Immunomodulation methods and compositions |
| US7556807B2 (en) | 2001-02-20 | 2009-07-07 | Kane Biotech, Inc. | Signal peptides, nucleic acid molecules and methods for treatment of caries |
| US7597895B2 (en) * | 2001-02-20 | 2009-10-06 | The Governing Council Of The University Of Toronto | Signal peptides, nucleic acid molecules and methods for treatment of caries |
| AU2002335932B2 (en) * | 2001-03-21 | 2007-11-01 | Altarex Medical Corp. | Therapeutic compositions that alter the immune response |
| US20030138434A1 (en) * | 2001-08-13 | 2003-07-24 | Campbell Robert L. | Agents for enhancing the immune response |
| CA2468878A1 (en) * | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their productionor generation |
| WO2003046011A1 (en) * | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate an antigen presenting cell contacted with such conjugate their use for vaccination or as medicament and methods for their production or generation |
| US20050260208A1 (en) * | 2002-04-11 | 2005-11-24 | Altarex Medical Corp. | Binding agents and their use in targeting tumor cells |
| US20040191843A1 (en) * | 2003-02-03 | 2004-09-30 | Palo Alto Institute Of Molecular Medicine | Cell-killing molecules and methods of use thereof |
| US9403908B2 (en) * | 2003-09-29 | 2016-08-02 | The Regents Of The University Of California | Method for altering hematopoietic progenitor cell adhesion, differentiation, and migration |
| JP2010524508A (ja) * | 2007-04-27 | 2010-07-22 | ダウ グローバル テクノロジーズ インコーポレイティド | 可溶性組換え二十面体ウイルス様粒子の生産及びインビボ組織化の改善 |
| US9750806B2 (en) | 2011-05-17 | 2017-09-05 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3063736D1 (en) * | 1979-03-27 | 1983-07-21 | Nat Res Dev | Improvements in or relating to immunological preparations |
| CA1203164A (en) * | 1982-03-09 | 1986-04-15 | Thomas J. Mckearn | Antibody conjugates |
| EP0142905A2 (de) * | 1983-03-30 | 1985-05-29 | Bio-Response Inc. | Therapeutisches Mittel für die Behandlung von Krankheiten wie Krebs |
| IL69686A (en) * | 1983-09-11 | 1988-03-31 | Yeda Res & Dev | Compositions containing cell membrane proteins and process for their preparation |
| JPS6072826A (ja) * | 1983-09-26 | 1985-04-24 | バイオ−レスポンス・インコ−ポレ−テツド | 疾患細胞の生体内治療物質 |
-
1986
- 1986-05-06 GB GB868610983A patent/GB8610983D0/en active Pending
-
1987
- 1987-05-05 EP EP87304005A patent/EP0245078B1/de not_active Expired - Lifetime
- 1987-05-05 DE DE8787304005T patent/DE3775458D1/de not_active Expired - Lifetime
- 1987-05-05 US US07/046,095 patent/US4950480A/en not_active Expired - Lifetime
- 1987-05-05 AT AT87304005T patent/ATE70717T1/de not_active IP Right Cessation
- 1987-05-06 JP JP62110400A patent/JPH0674210B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP0245078B1 (de) | 1991-12-27 |
| EP0245078A3 (en) | 1989-07-12 |
| JPS6345228A (ja) | 1988-02-26 |
| EP0245078A2 (de) | 1987-11-11 |
| US4950480A (en) | 1990-08-21 |
| DE3775458D1 (de) | 1992-02-06 |
| GB8610983D0 (en) | 1986-06-11 |
| JPH0674210B2 (ja) | 1994-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE70717T1 (de) | Vermehrung der antigenimmunogenizitaet. | |
| ATE510563T1 (de) | Künstliche t-helferzell-epitope als immunstimulatoren für synthetische peptidimmunogene | |
| DE3588022D1 (de) | Pre-S-Gen kodierte Hepatitis-B immunogene Peptide, Vakzine, Diagnostika und synthetische lipidische Bläschenträger. | |
| ATE317267T1 (de) | Impfstoffe mit erhöhter immunantwort und verfahren zur deren herstellung | |
| DK174416B1 (da) | Oligopeptider, immunogene konjugater heraf med et antigen samt vacciner indeholdende disse konjugater | |
| Thraenhart et al. | Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man | |
| Jemmerson et al. | Mapping antigenic sites on proteins: Implications for the design of synthetic vaccines. | |
| ATE47524T1 (de) | Hundeparvovirus-impfstoffe. | |
| ATE302016T1 (de) | Peptide, verwendet als träger in immunogenen konstrukten, die in der entwicklung synthetischer impfstoffe geeignet sind | |
| WO1998001558A3 (en) | Protein and peptide vaccines for inducing mucosal immunity | |
| Lopez-Macias et al. | Induction of antibodies against Salmonella typhi OmpC porin by naked DNA immunization | |
| EP0303309A3 (en) | A genus-specific listeria antigen identified by monoclonal antibodies | |
| Tabatabai et al. | Characterization of salt-extractable protein antigens from Brucella abortus by crossed immunoelectrophoresis and isoelectricfocusing | |
| ATE258986T1 (de) | Sekretorischer rekombinanter bcg impfstoff gegen aids | |
| Berthon et al. | Kinetics of the in vitro antibody response to transmissible gastroenteritis (TGE) virus from pig mesenteric lymph node cells, using the ELISASPOT and ELISA tests | |
| Petersen et al. | Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine | |
| ATE284897T1 (de) | Selfantigen-impfstoffe zur behandlung von b-zell lymphomen und sonstigen krebsen | |
| Hachimura et al. | Relative positioning of the T cell and B cell determinants on an immunogenic peptide: its influence on antibody response | |
| GB2314560A (en) | Synthetic peptides of m. gallisepticum, antibodies thereto, their preparations and use | |
| FI894048A0 (fi) | Menetelmä Pseudomonas aeruginosa-infektioita vastaan vaikuttavien valmisteiden sekä immunoglobuliini-G-pitoisten, Pseudomonas aeruginosa-bakteeria vastaan vaikuttavien valmisteiden tuottamiseksi | |
| IT1189295B (it) | Composizione antigenica sintetica e procedimento per la sua preparazione |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |